NervGen Pharma Corp Net Income
| NGENF Stock | USD 3.93 0.10 2.61% |
As of the 9th of February, NervGen Pharma secures the Downside Deviation of 4.32, risk adjusted performance of 0.129, and Mean Deviation of 4.31. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of NervGen Pharma Corp, as well as the relationship between them. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate nineteen technical drivers for NervGen Pharma, which can be compared to its peers in the industry. Please verify NervGen Pharma Corp information ratio, value at risk, as well as the relationship between the Value At Risk and expected short fall to decide if NervGen Pharma Corp is priced some-what accurately, providing market reflects its recent price of 3.93 per share. Given that NervGen Pharma Corp has jensen alpha of 0.6518, we recommend you to check NervGen Pharma's last-minute market performance to make sure the company can sustain itself at a future point.
NervGen Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing NervGen Pharma's valuation are provided below:NervGen Pharma Corp does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. NervGen |
NervGen Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to NervGen Pharma's otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of NervGen Pharma.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in NervGen Pharma on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding NervGen Pharma Corp or generate 0.0% return on investment in NervGen Pharma over 90 days. NervGen Pharma is related to or competes with JW (Cayman), Brii Biosciences, Genfit SA, Scancell Holdings, Molecular Partners, NDT Pharmaceuticals, and Innate Pharma. NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of ph... More
NervGen Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure NervGen Pharma's otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess NervGen Pharma Corp upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.32 | |||
| Information Ratio | 0.1342 | |||
| Maximum Drawdown | 34.14 | |||
| Value At Risk | (6.70) | |||
| Potential Upside | 11.62 |
NervGen Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for NervGen Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as NervGen Pharma's standard deviation. In reality, there are many statistical measures that can use NervGen Pharma historical prices to predict the future NervGen Pharma's volatility.| Risk Adjusted Performance | 0.129 | |||
| Jensen Alpha | 0.6518 | |||
| Total Risk Alpha | 0.2881 | |||
| Sortino Ratio | 0.1833 | |||
| Treynor Ratio | 0.3161 |
NervGen Pharma February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.129 | |||
| Market Risk Adjusted Performance | 0.3261 | |||
| Mean Deviation | 4.31 | |||
| Semi Deviation | 3.72 | |||
| Downside Deviation | 4.32 | |||
| Coefficient Of Variation | 669.33 | |||
| Standard Deviation | 5.9 | |||
| Variance | 34.8 | |||
| Information Ratio | 0.1342 | |||
| Jensen Alpha | 0.6518 | |||
| Total Risk Alpha | 0.2881 | |||
| Sortino Ratio | 0.1833 | |||
| Treynor Ratio | 0.3161 | |||
| Maximum Drawdown | 34.14 | |||
| Value At Risk | (6.70) | |||
| Potential Upside | 11.62 | |||
| Downside Variance | 18.66 | |||
| Semi Variance | 13.84 | |||
| Expected Short fall | (5.40) | |||
| Skewness | 1.31 | |||
| Kurtosis | 3.14 |
NervGen Pharma Corp Backtested Returns
NervGen Pharma appears to be risky, given 3 months investment horizon. NervGen Pharma Corp has Sharpe Ratio of 0.16, which conveys that the firm had a 0.16 % return per unit of risk over the last 3 months. By analyzing NervGen Pharma's technical indicators, you can evaluate if the expected return of 0.97% is justified by implied risk. Please exercise NervGen Pharma's Downside Deviation of 4.32, risk adjusted performance of 0.129, and Mean Deviation of 4.31 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, NervGen Pharma holds a performance score of 12. The company secures a Beta (Market Risk) of 2.76, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, NervGen Pharma will likely underperform. Please check NervGen Pharma's expected short fall, and the relationship between the value at risk and daily balance of power , to make a quick decision on whether NervGen Pharma's current price movements will revert.
Auto-correlation | -0.72 |
Almost perfect reverse predictability
NervGen Pharma Corp has almost perfect reverse predictability. Overlapping area represents the amount of predictability between NervGen Pharma time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of NervGen Pharma Corp price movement. The serial correlation of -0.72 indicates that around 72.0% of current NervGen Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.72 | |
| Spearman Rank Test | -0.74 | |
| Residual Average | 0.0 | |
| Price Variance | 0.47 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, NervGen Pharma Corp reported net income of (12.73 Million). This is 103.73% lower than that of the Healthcare sector and 118.17% lower than that of the Biotechnology industry. The net income for all United States stocks is 102.23% higher than that of the company.
NervGen Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NervGen Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of NervGen Pharma could also be used in its relative valuation, which is a method of valuing NervGen Pharma by comparing valuation metrics of similar companies.NervGen Pharma is currently under evaluation in net income category among its peers.
NervGen Fundamentals
| Return On Equity | -1.42 | |||
| Return On Asset | -0.67 | |||
| Current Valuation | 48.78 M | |||
| Shares Outstanding | 58.68 M | |||
| Shares Owned By Insiders | 25.27 % | |||
| Price To Book | 5.13 X | |||
| EBITDA | (11.33 M) | |||
| Net Income | (12.73 M) | |||
| Cash And Equivalents | 11.65 M | |||
| Cash Per Share | 0.20 X | |||
| Total Debt | 324.69 K | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 4.25 X | |||
| Book Value Per Share | 0.31 X | |||
| Cash Flow From Operations | (8.27 M) | |||
| Earnings Per Share | (0.28) X | |||
| Beta | 1.7 | |||
| Market Capitalization | 87.43 M | |||
| Total Asset | 17.9 M | |||
| Net Asset | 17.9 M |
About NervGen Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NervGen Pharma Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NervGen Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NervGen Pharma Corp based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in NervGen OTC Stock
NervGen Pharma financial ratios help investors to determine whether NervGen OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NervGen with respect to the benefits of owning NervGen Pharma security.